1. Catalog
  2. Don’t Fail Them Now: Bridging Diagnostic and Treat ...
Image For Activity Cover
Don’t Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis
Please claim your continuing education credit on the Peerview site!
Don’t Fail Them Now: Bridging Diagnostic and Treatment Gaps in Transthyretin Cardiac Amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) leads to cardiomyopathy due to the extracellular accumulation of misfolded transthyretin protein. Alarmingly, new epidemiologic studies suggest that specific genetic variants that cause the disease are far more common than previously suspected. Recent developments have led to the emergence of targeted therapies that alter the inevitable course of ATTR-CA, transforming it from a progressive, potentially fatal disease into a treatable one. However, healthcare providers must institute these therapies early to optimize outcomes. What’s most crucial for cardiologists to know about timely recognition and treatment?

During a recent live event, renowned cardiology experts shared their insights on the diagnostic and treatment process to give patients the best chance possible at long-term, favorable outcomes. This activity covers everything from identifying the signs and symptoms of ATTR-CA to early intervention using evidence-based guidelines and the creation of individualized treatment plans using the latest evidence. Don’t fail your patients now—if you couldn’t join us for the live event, watch this on-demand now and leave better equipped to care for patients with ATTR-CA!

Please claim your continuing education credits on the Peerview Site!

Please access the on-demand content here!
Summary
Cost: FREE
Credit:
No Credit Offered
Create Account
Recommended
Powered by Oasis.